- Email: [email protected]
neu expression in breast cancer patients
IAP 2014 ABSTRACTS
with abundance epithelioid cells with high mitotic activity in variably sized nodular architectures in myxoid matrix. Immunohistochemical studies show strongly positive for S-100 protein, scattered positive for EMA and focal immunoreactivity for cytokeratins. CD 34 and Bcl-2 were negative, leading us to diagnose high-grade extraskeletal myxoid chondrosarcoma. High-grade extraskeletal myxoid chondrosarcoma is a rare primary tumor in breast which resembles malignant cystosarcoma phyllodes and metaplastic carcinoma.
Breast Pathology: Poster#047 GRANULOCYTIC SARCOMA OF THE BREAST: A CASE STUDY IN LAO PDR Phaengvilay Xaysomphet1, Bounleng Kousonh1, Thitsamay Luangxay1, Phetsanone Aroulansy1, Moosa Khalil2, Prawat Nitiyanant3 and Suchin Worawichawong3 1Department of Pathology, Faculty of Medicine University of Health Science, LAO PDR, 2Department of Pathology and Laboratory Medicine, University of Calgary, Alberta, Canada, and 3Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Granulocytic sarcoma (GS) also called, myeloid sarcoma, chloroma, myeloblastoma or extra medullary myeloid tumor is an extra medullary hematopoietic neoplasm composed of immature myeloid cell (myeloblasts). GS may occur in leukemia, myeloproliferative disorder. GS can occur in any site of the body; common sites of involvement include bone, CNS, soft tissue, lymph nodes and skin, but breast is very rare. GS of breast have been reported both before and after hematological diagnosis. Primary, isolate or non-leukemic GS of breast was described when bone marrow biopsy to confirm as no other hematologic malignancy. Depending on review of all Medline cases reported, only 24 cases of primary were commonly in unilateral site, and only 4 cases were bilateral site. The incidence of GS of breast is 2/1,000,000 in adults and ages ranged from 16–72 years (mean 31 years). The histology was composed of homomorphous of eosinophil cytoplasm of immature cell with single or multiple nucleoli. The malignant cells were positive for myeloperoxidase (MPO), CD43, CD34, TDT, CD 117, CD68 and negative for CD20, CD30, CD3, CD56, CD79 and ULH1.The differential diagnosis included lymphoma and poorly differentiated carcinoma. The prognosis was very poor. We report a case of granulocytic sarcoma (GS) in the left breast of a 33-year-old woman who presented with breast mass, which was diagnosed as diffuse lymphoma, large cell type on H&E histopathology without any special straining, immunohistochemical and very limited of patient information such as echography, CBC, FNA or biopsy of breast or bone marrow tissue. The final diagnosis was made by additional immunohistochemical study.
Breast Pathology: Poster#048 IMPACT OF THE NOTTINGHAM PROGNOSTIC INDEX (NPI) ON THE OCCURRENCE OF RELAPSES COMPARED WITH THE HER-2/NEU EXPRESSION IN BREAST CANCER PATIENTS Dzengis N. Jasar, Katerina B. Kubelka-Sabit and Vanja A. Filipovski
S57
Department of Histopathology, Clinical Hospital Acibadem/ Sistina, Skopje, Macedonia Introduction: Aim of this study was to determine the influence of clinical, histopathological and immunohistochemical parameters and the Nottingham prognostic index (NPI) on the occurrence of relapses compared with the HER-2/neu overexpression in breast cancer patients. Materials and methods: In this study, 174 patients with primary breast cancer were analyzed in the period from June 2007 to June 2010. Clinical and histopathological parameters with the NPI, and additional immunohistochemical parameters were determined (HER-2/neu status, Ki67 and p53 protein product). During the follow-up period (42–80 months) relapses were observed in 38 patients (21.8%). Results: The age of patients ranged from 28–83 years (mean 55.48þ10.0). Positive lymph nodes were observed in 99 (57%) patients and in 70 (40%) patients; the tumor was poorly differentiated. HER-2/neu overexpression was observed in 33 (19%) patients, and in 13 (40%) of them, relapses were present. NPI was higher than 3.4 in 90% (30/33, HER2/neu positive patients) while HER-2/neu overexpression was associated with the tumor size, lymph-nodal status, mitotic index, degree of histological differentiation, lymph-vascular invasion, stage of the disease, Ki67, and p53 expression ( p < 0.05). Conclusion: NPI score is an excellent parameter to evaluate the course of disease in HER-2/neu positive breast cancer compared to occurrence of relapses.
Breast Pathology: Poster#049 INHIBITORY EFFECT OF MALAYSIAN JUNGLE [TUALANG] HONEY IN MODULATING EXPERIMENTAL BREAST CANCERS INDUCED BY N-METHYL-NNITROSOUREA (MNU) Nor Hayati Othman1, Sarfraz Ahmad1 and Siti Amrah Sulaiman2 1Department of Pathology, and 2Department of Pharmacology, School of Medical Sciences, Universiti Sains, Malaysia Introduction: Recent studies have shown that honey has anticancer properties in tissue culture and in-vivo animal experiment against different types of cancers. Only a few studies suggested that honey might be useful in modulating experimental breast carcinoma in vivo. Aim: To study the inhibitory effects of Malaysian Jungle Tualang honey (TH) on N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinogenesis. Methods: Fifty female Sprague-Dawley rats were randomly divided into 5 groups with 10 animals each (n ¼ 10); Group 1 did not receive MNU and did not receive honey (negative control); Group 2 received MNU but not honey (positive control). Groups 3, 4 and 5 were fed orally with 0.2, 1.0 or 2.0 g/kg body weight of Tualang Honey daily respectively from day 0 of the experimentation. Cancer induction using MNU was done on the 7th day and development of mammary cancer masses was charted. All rats in all groups were given rat chowder ad lib. The rats in Groups 3, 4 and 5 continued to receive honey until the 120th day when they were sacrificed and subjected to autopsy. The tumors were harvested for gross and histopathological examinations. Results: The total number of tumors developed in all groups was 105. The mean number of tumors developed per rat in Groups 2, 3,
Copyright © Royal College of pathologists of Australasia. Unauthorized reproduction of this article is prohibited.
with abundance epithelioid cells with high mitotic activity in variably sized nodular architectures in myxoid matrix. Immunohistochemical studies show strongly positive for S-100 protein, scattered positive for EMA and focal immunoreactivity for cytokeratins. CD 34 and Bcl-2 were negative, leading us to diagnose high-grade extraskeletal myxoid chondrosarcoma. High-grade extraskeletal myxoid chondrosarcoma is a rare primary tumor in breast which resembles malignant cystosarcoma phyllodes and metaplastic carcinoma.
Breast Pathology: Poster#047 GRANULOCYTIC SARCOMA OF THE BREAST: A CASE STUDY IN LAO PDR Phaengvilay Xaysomphet1, Bounleng Kousonh1, Thitsamay Luangxay1, Phetsanone Aroulansy1, Moosa Khalil2, Prawat Nitiyanant3 and Suchin Worawichawong3 1Department of Pathology, Faculty of Medicine University of Health Science, LAO PDR, 2Department of Pathology and Laboratory Medicine, University of Calgary, Alberta, Canada, and 3Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Granulocytic sarcoma (GS) also called, myeloid sarcoma, chloroma, myeloblastoma or extra medullary myeloid tumor is an extra medullary hematopoietic neoplasm composed of immature myeloid cell (myeloblasts). GS may occur in leukemia, myeloproliferative disorder. GS can occur in any site of the body; common sites of involvement include bone, CNS, soft tissue, lymph nodes and skin, but breast is very rare. GS of breast have been reported both before and after hematological diagnosis. Primary, isolate or non-leukemic GS of breast was described when bone marrow biopsy to confirm as no other hematologic malignancy. Depending on review of all Medline cases reported, only 24 cases of primary were commonly in unilateral site, and only 4 cases were bilateral site. The incidence of GS of breast is 2/1,000,000 in adults and ages ranged from 16–72 years (mean 31 years). The histology was composed of homomorphous of eosinophil cytoplasm of immature cell with single or multiple nucleoli. The malignant cells were positive for myeloperoxidase (MPO), CD43, CD34, TDT, CD 117, CD68 and negative for CD20, CD30, CD3, CD56, CD79 and ULH1.The differential diagnosis included lymphoma and poorly differentiated carcinoma. The prognosis was very poor. We report a case of granulocytic sarcoma (GS) in the left breast of a 33-year-old woman who presented with breast mass, which was diagnosed as diffuse lymphoma, large cell type on H&E histopathology without any special straining, immunohistochemical and very limited of patient information such as echography, CBC, FNA or biopsy of breast or bone marrow tissue. The final diagnosis was made by additional immunohistochemical study.
Breast Pathology: Poster#048 IMPACT OF THE NOTTINGHAM PROGNOSTIC INDEX (NPI) ON THE OCCURRENCE OF RELAPSES COMPARED WITH THE HER-2/NEU EXPRESSION IN BREAST CANCER PATIENTS Dzengis N. Jasar, Katerina B. Kubelka-Sabit and Vanja A. Filipovski
S57
Department of Histopathology, Clinical Hospital Acibadem/ Sistina, Skopje, Macedonia Introduction: Aim of this study was to determine the influence of clinical, histopathological and immunohistochemical parameters and the Nottingham prognostic index (NPI) on the occurrence of relapses compared with the HER-2/neu overexpression in breast cancer patients. Materials and methods: In this study, 174 patients with primary breast cancer were analyzed in the period from June 2007 to June 2010. Clinical and histopathological parameters with the NPI, and additional immunohistochemical parameters were determined (HER-2/neu status, Ki67 and p53 protein product). During the follow-up period (42–80 months) relapses were observed in 38 patients (21.8%). Results: The age of patients ranged from 28–83 years (mean 55.48þ10.0). Positive lymph nodes were observed in 99 (57%) patients and in 70 (40%) patients; the tumor was poorly differentiated. HER-2/neu overexpression was observed in 33 (19%) patients, and in 13 (40%) of them, relapses were present. NPI was higher than 3.4 in 90% (30/33, HER2/neu positive patients) while HER-2/neu overexpression was associated with the tumor size, lymph-nodal status, mitotic index, degree of histological differentiation, lymph-vascular invasion, stage of the disease, Ki67, and p53 expression ( p < 0.05). Conclusion: NPI score is an excellent parameter to evaluate the course of disease in HER-2/neu positive breast cancer compared to occurrence of relapses.
Breast Pathology: Poster#049 INHIBITORY EFFECT OF MALAYSIAN JUNGLE [TUALANG] HONEY IN MODULATING EXPERIMENTAL BREAST CANCERS INDUCED BY N-METHYL-NNITROSOUREA (MNU) Nor Hayati Othman1, Sarfraz Ahmad1 and Siti Amrah Sulaiman2 1Department of Pathology, and 2Department of Pharmacology, School of Medical Sciences, Universiti Sains, Malaysia Introduction: Recent studies have shown that honey has anticancer properties in tissue culture and in-vivo animal experiment against different types of cancers. Only a few studies suggested that honey might be useful in modulating experimental breast carcinoma in vivo. Aim: To study the inhibitory effects of Malaysian Jungle Tualang honey (TH) on N-methyl-N-nitrosourea (MNU)-induced rat mammary carcinogenesis. Methods: Fifty female Sprague-Dawley rats were randomly divided into 5 groups with 10 animals each (n ¼ 10); Group 1 did not receive MNU and did not receive honey (negative control); Group 2 received MNU but not honey (positive control). Groups 3, 4 and 5 were fed orally with 0.2, 1.0 or 2.0 g/kg body weight of Tualang Honey daily respectively from day 0 of the experimentation. Cancer induction using MNU was done on the 7th day and development of mammary cancer masses was charted. All rats in all groups were given rat chowder ad lib. The rats in Groups 3, 4 and 5 continued to receive honey until the 120th day when they were sacrificed and subjected to autopsy. The tumors were harvested for gross and histopathological examinations. Results: The total number of tumors developed in all groups was 105. The mean number of tumors developed per rat in Groups 2, 3,
Copyright © Royal College of pathologists of Australasia. Unauthorized reproduction of this article is prohibited.